coronavirus
singlestrand
rna
virus
associ
mild
sever
respiratori
symptom
human
coronavirus
hcov
strain
first
describ
caus
respiratori
tract
infect
human
includ
common
cold
pneumonia
new
human
coronaviru
name
sarscov
identifi
etiolog
agent
global
outbreak
sever
acut
respiratori
syndrom
sar
caus
death
individu
among
case
worldwid
repres
fatal
rate
almost
sinc
three
addit
coronavirus
recogn
initi
report
caus
acut
respiratori
diseas
lower
sever
compar
sarscov
recent
middl
east
respiratori
syndrom
merscov
caus
lethal
respiratori
diseas
date
approv
antivir
drug
vaccin
avail
prevent
treatment
sarslik
virus
make
develop
effect
antivir
agent
imper
need
coronavirus
express
two
proteas
papainlik
proteas
pl
pro
proteas
pro
pro
enzym
also
refer
main
proteas
pro
essenti
intracellular
viral
replic
make
attract
target
develop
novel
inhibitor
report
literatur
classifi
potenti
antivir
compound
two
main
categori
peptidomimet
fig
ii
small
moleculebas
inhibitor
fig
present
activ
nm
rang
despit
satisfi
initi
result
major
promis
compound
proceed
clinic
studi
due
nonid
physicochem
properti
refer
nonpeptid
inhibitor
accentu
presenc
benzotriazol
group
import
benzotriazol
motif
reli
format
key
interact
catalyt
dyad
pro
activ
site
consid
interest
chemistri
bioactiv
molecul
interest
bind
mode
want
prepar
novel
librari
fuse
subsequ
determin
biolog
activ
report
preliminari
result
develop
novel
seri
fuse
compound
potenti
antivir
activ
purpos
implement
multicompon
reaction
develop
within
group
result
plethora
deriv
singl
step
start
readili
avail
enoliz
carbonyl
compound
primari
amin
azid
gener
method
proce
via
equilibrium
imin
enamin
follow
cycloaddit
azid
lead
triazolin
intermedi
elimin
result
final
fuse
analogu
synthesi
present
scheme
began
follow
gener
method
gener
oxopiperidin
carboxyl
intermedi
involv
michael
addit
anilin
onto
ethyl
acryl
follow
intramolecular
dieckmann
condens
subsequ
nucleophil
substitut
benzyl
bromid
provid
start
materi
overal
yield
obtain
proceed
fuse
triazol
format
use
collect
primari
amin
azid
pna
commenc
investig
benzyl
amin
bear
electrondon
function
group
tabl
c
electronwithdraw
group
tabl
famili
obtain
moder
good
yield
analysi
use
heterocycl
aliphat
deriv
prove
applic
substitu
high
temperatur
condit
use
reaction
tabl
furthermor
examin
influenc
introduct
fluoro
group
benzyl
bromid
reactiv
tabl
entri
demonstr
effect
outcom
reaction
second
seri
fuse
analogu
prepar
base
previous
describ
multicompon
method
start
materi
turn
synthes
accord
buchwaldhartwig
pdcatalyz
amin
differ
aryl
bromid
present
scheme
initi
examin
scope
reaction
respect
primari
amin
would
expect
base
aforement
result
manag
synthes
adequ
number
exampl
good
excel
yield
furthermor
presenc
electron
withdraw
substitu
aryl
bromid
explor
result
summar
tabl
compound
evalu
broad
varieti
virus
includ
strain
iii
b
strain
rod
cell
herp
simplex
viru
type
strain
ko
herp
simplex
viru
type
strain
g
herp
simplex
viru
tk
ko
acv
re
vaccinia
viru
adeno
coronaviru
hel
cell
inhibitori
activ
compar
refer
compound
zidovudin
brivudin
b
small
molecul
sarscov
pro
inhibitor
scheme
synthet
pathway
toward
deriv
reagent
condit
acoh
cucl
h
b
nah
toluen
etoh
h
c
bnbr
k
co
thf
h
toluen
h
cidofovir
acyclovir
ganciclovir
zalcitabin
alovudin
urtica
dioica
agglutinin
uda
respect
compound
inact
toward
test
virus
ec
ec
ec
ec
ec
show
moder
activ
human
coronaviru
approxim
fold
lower
activ
observ
uda
ec
alter
normal
cell
morpholog
confluent
hel
cell
cultur
observ
concentr
data
shown
select
index
si
mcc
ec
ratio
activ
compound
determin
structureact
relationship
sar
synthes
librari
fuse
utmost
import
identifi
key
intermolecular
contact
involv
noncoval
interact
pro
structur
divers
inhibitor
aim
sever
molecular
model
techniqu
includ
molecular
dock
molecular
dynam
free
energi
bind
analys
intermolecular
interact
scan
appli
search
sar
knowledg
first
stage
previous
report
pro
noncoval
inhibitor
model
order
defin
key
intermolecular
interact
requir
enzym
inhibit
second
stage
silico
analysi
extend
famili
fuse
present
report
catalyt
activ
pro
well
character
extens
detail
regard
structur
enzym
correspond
catalyt
site
respect
known
activ
site
locat
within
domain
ii
catalyt
dyad
consist
residu
locat
also
previous
report
catalyt
site
pro
exhibit
stereoselect
recognit
noncoval
inhibitor
context
molecular
model
protocol
initi
explor
bind
mode
intermolecular
interact
pattern
stereoselect
noncoval
inhibitor
pro
deposit
protein
databank
code
enantiom
bound
ligand
dock
within
catalyt
site
seen
fig
b
r
enantiom
result
ident
interact
pattern
observ
experiment
obtain
crystal
ligand
bind
stabil
sever
hydrophob
hydrogen
bond
hb
interact
particular
relev
noteworthi
enantiom
also
abl
establish
sever
hydrophob
interact
abl
establish
hb
take
account
previous
report
r
enantiom
activ
find
suggest
establish
interact
constitut
critic
featur
inhibit
catalyt
activ
enzym
studi
persist
hb
interact
intermolecular
complex
subject
molecular
dynam
md
analysi
tabl
present
persist
valu
hb
calcul
md
trajectori
seen
tabl
entri
r
enantiom
abl
maintain
rel
high
frequenc
hb
interact
enantiom
rearrang
bind
contact
persist
find
valid
molecular
model
workflow
develop
ie
crystallograph
bind
pose
reproduc
also
strongli
suggest
least
two
stabl
electrostat
interact
within
activ
site
requir
effect
pro
inhibit
studi
hypothesi
set
previous
report
pro
inhibitor
contain
fuse
triazol
ring
exhibit
wide
rang
inhibitori
activ
ie
nm
tabl
subject
molecular
model
workflow
lowest
energi
bind
mode
obtain
agreement
report
crystallograph
structur
fig
pdb
code
respect
support
adequ
parametr
simul
condit
molecular
model
protocol
inspect
correspond
lowest
energi
dock
pose
whole
set
compound
fig
observ
inhibitor
inde
abl
establish
two
hb
previous
describ
ie
one
backbon
anoth
one
side
chain
bind
mode
triazol
ring
posit
proxim
catalyt
dyad
md
simul
quantif
persist
mention
hydrogen
bond
interact
tabl
entri
observ
compound
maintain
hydrogen
bond
requir
inhibit
pro
high
frequenc
particular
noteworthi
inhibitor
enantiomer
pure
exhibit
submicromolar
activ
maintain
high
frequenc
hb
particular
far
potent
compound
within
train
set
exhibit
also
singl
cluster
dock
pose
suggest
effici
pharmacodynam
interact
pro
also
adequ
conform
preorgan
compliant
correspond
bioactiv
conform
compound
subject
molecular
model
workflow
order
studi
whether
pro
may
repres
plausibl
molecular
target
observ
antivir
activ
fig
show
lowest
energi
bind
mode
pro
found
compound
dock
pose
correspond
bioactiv
deriv
observ
e
fig
respect
seen
establish
two
hb
interact
posit
also
triazol
ring
proxim
catalyt
dyad
discuss
previou
section
interact
pattern
requir
inhibit
pro
catalyt
activ
suggest
enzym
may
antivir
target
fuse
analysi
md
also
show
interact
maintain
throughout
simul
support
bioactiv
tabl
entri
contrast
fuse
triazol
deriv
exhibit
antivir
activ
infect
cell
establish
two
hb
interact
lowest
energi
bind
pose
abl
form
simul
trajectori
subject
md
assay
compound
constitut
two
except
behavior
bear
methoxi
substitu
para
posit
phenyl
ring
substitut
triazol
central
scaffold
two
compound
abl
establish
maintain
hb
interact
pattern
requir
pro
inhibit
tabl
entri
exhibit
antivir
activ
fact
may
due
disfavor
entrop
contribut
upon
bind
pro
catalyt
site
sinc
order
maintain
interact
rotat
methoxi
group
constrain
within
dihedr
angl
clearli
entrop
cost
present
bioactiv
analogu
bear
fluorin
atom
para
posit
deriv
analyz
fig
similar
behavior
observ
deriv
exhibit
antivir
activ
ie
abl
establish
two
stabl
hb
interact
within
catalyt
site
pro
fig
particular
deriv
anchor
within
catalyt
site
stabl
interact
two
addit
interact
establish
regard
interact
compound
establish
stabl
hb
contact
anchor
residu
result
compound
posit
fuse
triazol
scaffold
vicin
catalyt
dyad
consist
block
proteas
activ
enzym
final
interact
pattern
inact
compound
within
seri
analyz
found
fail
establish
two
requir
hb
interact
within
catalyt
site
enzym
conclus
succeed
synthes
novel
librari
fuse
use
inhous
develop
multicompon
reaction
librari
subject
vitro
analysi
use
broad
varieti
virus
determin
antivir
properti
silico
studi
determin
interact
pro
compound
show
moder
activ
coronaviru
molecular
model
work
flow
develop
base
previous
report
pro
noncoval
inhibitor
help
identif
key
molecular
interact
applic
model
librari
support
antivir
activ
mediat
inhibit
pro
addit
studi
structureact
relationship
enabl
us
prepar
new
fuse
deriv
enhanc
antivir
properti
work
support
katholiek
universiteit
leuven
ku
leuven
grant
addit
author
grate
acknowledg
financi
support
secretaria
de
ciencia
universidad
nacion
de
secytunc
consejo
nacion
de
investigacion
conicet
agencia
nacion
de
anpcyt
author
would
also
like
thank
gpgpu
comput
group
facultad
de
famaf
universidad
nacion
de
argentina
provid
access
comput
resourc
author
also
grate
acknowledg
support
nvidia
corpor
donat
titan
xp
gpu
use
research
mario
quevedo
wish
thank
openey
scientif
softwar
free
academ
licens
program
provid
licens
use
correspond
softwar
packag
